By Kim Richters

 

Novartis AG's Phase 3 Canopy-A study for canakinumab as adjuvant treatment in non-small cell lung cancer didn't meet the primary endpoint of disease-free survival versus placebo.

The Swiss pharmaceutical company said Monday that it will present findings from the study, which concerned patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer, at an upcoming medical meeting.

 

Write to Kim Richters at kim.richters@wsj.com

 

(END) Dow Jones Newswires

August 15, 2022 01:50 ET (05:50 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Sep 2022 a Oct 2022 Haga Click aquí para más Gráficas Novartis.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Oct 2021 a Oct 2022 Haga Click aquí para más Gráficas Novartis.